News

A triple combination of an investigational drug that enables immune cells to infiltrate tumors, an immunotherapy drug and chemotherapy showed promising responses in patients with the most common type of metastatic pancreatic cancer, according to data from an international phase 2a clinical trial led by Weill Cornell Medicine and Beth Israel Deaconness Medical Center investigators.

As the first wave of the COVID-19 pandemic begins to subside in parts of the United States, doctors around the country and especially in hard-hit New York City are reporting cases of an apparently related inflammatory syndrome. 

In March, as the COVID-19 pandemic gained a visible foothold in New York City, Weill Cornell Medicine and NewYork-Presbyterian faced a task unlike any they had encountered before: How would they quickly establish a reliable diagnostic testing program to identify patients and healthcare workers who had been exposed to SARS-CoV-2 amid a rapidly escalating public health crisis? 

Higher levels of a type of fungus in the gut are associated with better outcomes for patients with a type of inflammatory bowel disease called ulcerative colitis who are treated with gut microbes from healthy donors.

Neurologists traditionally have expected that patients who remain in coma after cardiac arrest have almost no chance of making a meaningful recovery if they fail to emerge from coma within a week.

As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.

Physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to confront the COVID-19 pandemic, focusing a broad spectrum of expertise on the critical issues the disease is posing to healthcare workers and public health officials.

Although COVID-19 is a threat to everyone, people of color have been hit especially hard by the virus — what has been called a “pandemic within the pandemic.”

COVID-19 almost always starts with relatively mild, flu-like symptoms that can be treated at home. People who have these symptoms usually do not need to be tested to confirm the infection.

Among the confounding aspects of the novel coronavirus is the wide range of disease severity patients experience. While a minority of COVID-19 patients require hospitalization, the effects of infection for these people are dramatic and in some cases life threatening. 

With the goal of advancing the fight against COVID-19, the Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from the disease and identify new cases of it.

Our Q&A video series provides information and advice from experts in different areas of medicine

An iron-regulating molecule called hepcidin is produced by the immune system and restricts the growth of gut bacteria after an intestinal injury, helping to heal the lining of the intestine, according to a study by Weill Cornell Medicine, NewYork-Presbyterian and Institut Cochin investigators.

Mathematical modeling by Weill Cornell Medicine is helping to guide New York State and New York City leaders as they make decisions that could affect the trajectory of the COVID-19 pandemic.

Scientists have known for years that HIV, the virus that causes AIDS, is difficult to cure because it hides from the body’s immune system. Research now reveals that the virus conceals itself in lymphocytes, or white blood cells, that are intrinsically hard to kill because they are resistant to killer T cells.

Gene mutations that are thought to be very early events in the development of leukemias and other blood disorders appear to set the stage for malignancy by increasing the production of certain types of blood cells at the expense of others.

Ion channels, which allow potassium and sodium ions to flow in and out of cells, are crucial in neuronal ‘firing’...

The fourth annual NYC Health Hackathon brought together students and faculty members from Weill Cornell Medicine, Cornell’s Ithaca campus and several local and national academic institutions, to develop high-tech healthcare innovations. 

Winner of a prestigious fellowship for postdocs, Dr. Adrian Jinich aims to spur health in developing countries—and inspire the next generation of STEM students.

Preclinical work suggests the targeted drug palbociclib may boost the effectiveness of chemotherapy in pancreatic cancer if the two treatments are given in the right sequence.